For cancer patients, Friedlander et al. first reported that whole-blood transcriptomics could predict clinical response to tremelimumab (anti-CTLA-4) in patients with advanced melanoma using the largest recent cohort [22]. This evidence concerns the gene CTLA4 and melanoma.